Jefferies lowered the firm’s price target on Procept BioRobotics (PRCT) to $77 from $95 and keeps a Hold rating on the shares after a “modest” Q4 beat and the company issuing FY25 sales guidance of $320M that beat consensus. The firm tweaks its estimates to reflect the guidance, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics price target lowered to $85 from $99 at TD Cowen
- Strong Growth Potential for PROCEPT BioRobotics Amid Market Challenges
- Procept BioRobotics price target lowered to $95 from $105 at Morgan Stanley
- Procept BioRobotics price target lowered to $90 from $105 at Truist
- Positive Outlook for PROCEPT BioRobotics: Resilience and Growth Opportunities Justify Buy Rating